Key result
Preoperative SGLT2 inhibitors linked to ~15% lower odds of postoperative AKI after major GI surgery.
Why the study?
SGLT2 inhibitors are increasingly used in patients with T2DM, but their association with postoperative acute kidney injury and other surgical outcomes following major gastrointestinal surgery remains uncertain.
Does preoperative SGLT2 inhibitor use reduce postoperative acute kidney injury within 7 days in adults with type 2 diabetes mellitus undergoing major gastrointestinal surgery?
Cohort (n=201,123)
Yes
Does preoperative SGLT2 inhibitor use reduce postoperative acute kidney injury within 7 days in adults with type 2 diabetes mellitus undergoing major gastrointestinal surgery?
In patients with T2DM undergoing major GI surgery, preoperative SGLT2 inhibitor use is associated with lower odds of postoperative AKI and mortality, though it increases the risk of postoperative diabetic ketoacidosis.
Answers are grounded in this paper and cite their sources.
Preoperative SGLT2 inhibitor use was associated with lower postoperative AKI odds in T2DM GI surgery; extends prior renal observations but remains hypothesis-generating pending RCTs.
BACKGROUND: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are increasingly used in patients with type 2 diabetes mellitus (T2DM) and may have established cardiovascular and renal benefits. However, the association with postoperative kidney injury and other surgical outcomes remains uncertain. We evaluated the association between preoperative SGLT2 inhibitor use and postoperative outcomes among patients with T2DM undergoing major gastrointestinal (GI) surgery. METHODS: Epic Cosmos, a multicenter electronic health record database, was used to identify adults with T2DM who underwent major GI surgical procedure between 2018 and 2024. Preoperative SGLT2 inhibitor exposure was defined as continuous use during the 6 months before surgery, allowing interruptions of less than 5 days. The primary outcome was AKI within 7 days after surgery, identified using ICD-10 diagnosis codes, with creatinine-based AKI assessed as a complementary outcome. Entropy balancing and weighted regression models were used to evaluate associations between SGLT2 inhibitor use and postoperative outcomes. RESULTS: Among 201,123 patients, 11,750 had qualifying preoperative SGLT2 inhibitor exposure and 189,373 did not. ICD-10-based AKI occurred in 17.4% of SGLT2 inhibitor users and 21.2% of nonusers. After entropy balancing, SGLT2 inhibitor use was associated with lower odds of ICD-10-based AKI (OR, 0.85; 95% CI, 0.81-0.89) and creatinine-based AKI (OR, 0.87; 95% CI, 0.82-0.92). SGLT2 inhibitor use was also associated with lower odds of prolonged length of stay (OR, 0.77; 95% CI, 0.73-0.81), ICU stay (OR, 0.90; 95% CI, 0.85-0.95), 30-day mortality (OR, 0.42; 95% CI, 0.35-0.49), and 90-day mortality (OR, 0.50; 95% CI, 0.44-0.56), and higher odds of discharge home (OR, 1.38; 95% CI, 1.32-1.44). In contrast, SGLT2 inhibitor use was associated with higher odds of DKA within 7 days after surgery (OR, 3.59; 95% CI, 300.07-4.18). CONCLUSIONS: Among patients with T2DM undergoing a major GI surgical procedure, preoperative SGLT2 inhibitor use was associated with lower postoperative AKI but higher DKA. These data may help inform perioperative use SGLT2 inhibitors among patients undergoing GI surgery.
No takes yet. Share an insight, caveat, or question.
Hussain et al. (2026) conducted a cohort in Type 2 diabetes mellitus undergoing major gastrointestinal surgery (n=201,123). Preoperative SGLT2 inhibitor use vs. No preoperative SGLT2 inhibitor use was evaluated on Acute kidney injury (AKI) within 7 days after surgery, identified using ICD-10 diagnosis codes (OR 0.85, 95% CI 0.81-0.89). Preoperative SGLT2 inhibitor use was associated with lower odds of 7-day postoperative ICD-10-based AKI after major GI surgery.
Synapse has enriched 10 related papers. Consider them for comparative context: